psoriasis Archives - Page 2 of 4

Anti-IL-17 monoclonal antibodies and bullous pemphigoid: treatment or causal agents? A case series and review of the literature

Anna Paola Lugli, Giacomo Caldarola, Gennaro Marco Falco, Costanza Montedoro, Camilla Mulas, Clara De Simone

Article Type

Case Series

Published

30 Jul 2024

This article describes two cases of new-onset bullous pemphigoid in two patients treated with anti-IL-17 drugs for psoriasis.

Rapid response on facial psoriasis to bimekizumab: case series

Nicoletta Bernardini, Annunziata Dattola, Giacomo Caldarola, Diego Orsini, Chiara Assorgi, Alessandra D’Amore, Giulia Maretti, Antonio Giovanni Richetta, Ersilia Tolino, Nevena Skroza, Concetta Potenza

Article Type

Case Series

Published

23 May 2024

This case series represents the first clinical real-life experience of rapid and successful management of facial psoriasis with bimekizumab in six patients.

A narrative review of fixed combination calcipotriol/betamethasone aerosol foam (Enstilar®) in the management of psoriasis with scalp involvement

Petra Staubach, Andreas Körber, Ralph M Trüeb, Caroline Mann, Ralph von Kiedrowski

Article Type

Review

Published

15 May 2024

In this narrative review, the authors evaluate available data on the use of an innovative aerosol foam formulation of calcipotriol plus betamethasone dipropionate (Cal/BD) to treat patients with psoriasis and scalp involvement.

Tildrakizumab for the treatment of moderate-to-severe psoriasis: a 52-week, real-world Portuguese multicentric study

Tiago Torres, Paulo Varela, Pedro Mendes Bastos, Sofia Magina, Martinha Henrique, Paulo Ferreira

Article Type

Original Research

Published

18 Mar 2024

This study aimed to evaluate the effectiveness of tildrakizumab in treating moderate-to-severe psoriasis within a real-world setting over a 52-week period in Portugal.

Effectiveness of risankizumab in the treatment of palmoplantar psoriasis: a 52-week Italian real-life experience

Giacomo Caldarola, Arianna Zangrilli, Gerardo Palmisano, Mauro Bavetta, Gaia Moretta, Gianluca Pagnanelli, Vincenzo Panasiti, Luca Bianchi, Clara De Simone, Ketty Peris

Article Type

Review

Published

13 Apr 2023

This multicentre, retrospective study evaluates the efficacy and safety of risankizumab in a population of psoriatic patients with palmoplantar involvement over a 52-week treatment period.